This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $103.38 in the latest trading session, marking a +0.29% move from the prior day.
Abbott (ABT) Stock Moves -0.83%: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $99.84, marking a -0.83% move from the previous day.
Abbott (ABT) Reports Favorable Findings From RELIEF Study
by Zacks Equity Research
The latest data from the RELIEF Study suggests a lower rate of hospitalizations from serious diabetes-related events with Abbott's (ABT) FreeStyle Libre system.
Aurora Cannabis Inc. (ACB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of 33.33% and 0.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $104.09, marking a +0.09% move from the previous day.
Top Stock Reports for Alphabet, JPMorgan & Coca-Cola
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), JPMorgan Chase & Co. (JPM) and The Coca-Cola Company (KO).
Do Options Traders Know Something About Abbott (ABT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Abbott (ABT) stock based on the movements in the options market lately.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $109.29, moving +0.75% from the previous trading session.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Strong results across the EPD, diagnostics and medical devices businesses are driving Abbott's (ABT) top line.
Abbott (ABT) Debuts Amplatzer Talisman System in Europe
by Zacks Equity Research
Abbott's (ABT) Amplatzer Talisman PFO Occlusion System will enable doctors across Europe to treat people experiencing a patent foramen ovale-associated stroke.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $102.71, marking a +0.2% move from the previous day.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $102.65, marking a +0.44% move from the previous day.
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $105.89, moving +0.43% from the previous trading session.
Abbott (ABT) to Offer New Treatment Option for Chronic Pain
by Zacks Equity Research
Abbott's (ABT) Proclaim Plus SCS system with FlexBurst360 therapy will cater to the changing needs of patients with chronic pain.
Abbott (ABT) Down 0.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights JPMorgan Chase, AbbVie, Abbott Laboratories, Intuit and Caterpillar
by Zacks Equity Research
JPMorgan Chase, AbbVie, Abbott Laboratories, Intuit and Caterpillar are included in this Analyst Blog.
Top Analyst Reports for JPMorgan Chase, AbbVie & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including JPMorgan Chase & Co. (JPM), AbbVie Inc. (ABBV) and Abbott Laboratories (ABT).
Thermo Fisher (TMO) Debuts Assay for Research on HIV Strains
by Zacks Equity Research
Thermo Fisher's (TMO) novel Applied Biosystems HIV-1 Genotyping Kit will aid in the global efforts to monitor the evolution of HIV.
3 MedTech Stocks That are Likely to Beat This Earnings Season
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how STE, TMO and IDXX are poised ahead of their earnings releases.
The Zacks Analyst Blog Highlights Visa, Abbott Laboratories, Salesforce, Wells Fargo and Centene
by Zacks Equity Research
Visa, Abbott Laboratories, Salesforce, Wells Fargo and Centene are included in this Analyst Blog.
Top Research Reports for Visa, Abbott & Salesforce
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Abbott Laboratories (ABT) and Salesforce, Inc. (CRM).
Abbott's (ABT) Q2 Earnings Top Estimates, '22 EPS View Up
by Zacks Equity Research
Abbott (ABT) reports better-than-expected results for Q2 2022, with robust contributions from the Established Pharmaceuticals, Diagnostics and Medical Device segments.
Pre-Market Gives Back Some Gains; Abbott Beats, Raises
by Mark Vickery
At this hour, the Dow is -110 points, while the Nasdaq is -20 and the S&P 500 is -15 points. It¿¿¿s a relatively mild give-back, but it's also early.
Earnings Season Gathers Pace, Home Sales Numbers Awaited
by Zacks Equity Research
Earnings Season Gathers Pace, Home Sales Numbers Awaited.